Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 27, 2025
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 27, 2025
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis …
Route 92 Medical Receives Australian Therapeutic Goods Administration Approval for its Portfolio of Neurovascular Interventional Products for Treating Patients with Acute Ischemic Stroke
GlobeNewswire
·
March 27, 2025
SAN MATEO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced approval from the Australian …
Curonix Unveils NervPulse™ Therapy: Setting a New Standard in Nerve-Specific Peripheral Nerve Stimulation (PNS) Therapy
GlobeNewswire
·
March 27, 2025
POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in relieving chronic pain without the use of opioids, proudly introduces NervPulse™ Therapy, an advanced, evidence-based programming …
Vivani Medical Announces $8.25M Private Placement Equity Financing
GlobeNewswire
·
March 27, 2025
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, …
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 27, 2025
Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approximately $490 million …
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
GlobeNewswire
·
March 27, 2025
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( …
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
GlobeNewswire
·
March 27, 2025
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth …
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 27, 2025
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV …
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
GlobeNewswire
·
March 27, 2025
– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” …
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results
GlobeNewswire
·
March 27, 2025
Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One HIFU procedures grew 51% on a year-over-year basis …
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewswire
·
March 27, 2025
FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its …
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
GlobeNewswire
·
March 27, 2025
NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study …
Immatics Announces Full Year 2024 Financial Results and Business Update
GlobeNewswire
·
March 27, 2025
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as planned ACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October …
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
GlobeNewswire
·
March 27, 2025
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid …
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 27, 2025
WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025. 24th Annual …
Vanqua Bio to Present at the AD/PD™ 2025 International Conference
GlobeNewswire
·
March 27, 2025
CHICAGO, March 27, 2025 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, …
Microbix Announces Annual and Special Meeting Voting Results
GlobeNewswire
·
March 27, 2025
MISSISSAUGA, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the “Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of …
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
GlobeNewswire
·
March 27, 2025
WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
GlobeNewswire
·
March 27, 2025
BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND …
Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
GlobeNewswire
·
March 27, 2025
CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M. …